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Abstract
Objective: Whether activation or inhibition of the mTOR pathway is beneficial
to ischemic injury remains controversial. It may result from the different reac-
tion of ischemic penumbra and core to modulation of mTOR pathway after
cerebral ischemia–reperfusion injury in rats. Methods: Longa’s middle cerebral
artery occlusion (MCAO) method was conducted to induce the focal cerebral
ischemia–reperfusion. Western blot analysis was used to examine the protein
expression involving mTOR pathway, apoptosis, and autophagy-related pro-
teins. TTC staining and Fluoro-Jade B staining was conducted to detect the
infarct volume and cell apoptosis, respectively. Neurological function was mea-
sured by modified neurological severity score and left-biased swing. Results:
mTOR signaling pathway was activated in ischemic penumbra and decreased in
ischemic core after ischemia and ischemia–reperfusion. Ischemia–reperfusion
injury induced the increase in cleaved caspase 9 and caspase 3 both in ischemic
penumbra and in ischemic core, whereas the expression of phosphorylated
ULK1, Beclin 1 and LC3-II was decreased. Rapamycin pre or postadministra-
tion inhibited the overactivation of mTOR pathway in ischemic penumbra.
Ameliorated neurological function and reduced infarct volume were observed
after pre or postrapamycin treatment. Rapamycin markedly decreased the num-
ber of FJB-positive cells and the expression of cleaved caspase-3 and cleaved
caspase-9 proteins as well as increased the activation of autophagy reflected by
ULK1, Beclin-1 and LC3. Interpretation: mTOR signaling pathway was acti-
vated in ischemic penumbra after cerebral ischemia–reperfusion injury in rats.
mTOR inhibitor rapamycin significantly decreased the mTOR activation and
infarct volume and subsequently improved neurological function. These results
may relate to inhibition of neuron apoptosis and activation of autophagy.
Introduction
Stroke is the second most common cause of death and
major cause of disability around the world. Brain
ischemic stroke is caused by pathophysiological thrombo-
sis and thromboembolism, which give rise to cerebral
arterial occlusion with subsequent ischemia of partial
brain tissue supplied by that artery.1,2 Although tremen-
dous progress has been made in the study of pathophysi-
ology on ischemic stroke, translation of basic research
into clinical therapies has not successed. Currently, sys-
temic thrombolysis with recombinant intravenous tissue
plasminogen activator (rtPA) remains a frequently used
therapy which can improve clinical outcome of patients
with acute ischemic stroke.3,4 However, rtPA has an
increased risk of hemorrhage beyond a few hours of post-
stroke, and only less than 4% of stroke patients can bene-
fit from it.5,6 Therefore, it is urgent to clarify the
mechanism of ischemic stroke and explore new potential
targeted strategies for the treatment of stroke.
The mammalian target of rapamycin (mTOR) pathway
plays an essential role in a number of important physio-
logical functions including cell growth, proliferation, pro-
tein synthesis, metabolism, and autophagy.7 In the brain,
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the mTOR pathway regulates synaptic plasticity, neuronal
transmission, axon outgrowth, neuronal size, and spine
morphology, thus loss of homeostasis of mTOR pathway
is involved in a variety of neurologic diseases such as epi-
lepsy, Alzheimer’s disease, and Parkinson’s disease.7–10
Numerous reports have demonstrated that mTOR path-
way is involved in brain ischemia–reperfusion induced
injury.11–16 However, whether upregulating or downregu-
lating mTOR pathway has a protective effect on neurons
in ischemia–reperfusion injury remains controversial.
Some studies have shown that upregulating mTOR offers
neuronprotection,11–13 whereas others have reported that
inhibiting mTOR by rapamycin administration reduces
neurological damage and promotes neuronal viability in
some ischemic models.14–16 The contradictory results
indicate that the subtle balance of mTOR signaling path-
way in cerebral ischemia is critical to cellular physiology.
However, the change in the mTOR signaling pathway in
different brain areas and in different time intervals after
ischemia–reperfusion has not been examined in detail,
thus it is possible that regulating the mTOR pathway at
different stages results in opposing effects. Therefore, in
this study, we explored the changes of key proteins of
mTOR signaling pathway in different regions and differ-
ent stages after cerebral ischemia–reperfusion (I/R) injury
using middle cerebral artery occlusion (MCAO) in rats,
and observed the effects and possible mechanism of
action of rapamycin on cerebral I/R injury in rats.
Materials and Methods
Animals
Male Sprague–Dawley (SD) rats weighing 230–270 g were
purchased from Shanghai Slac Laboratory Animal Corpo-
ration (certificate: SCXK2007-0005) and housed at Zhe-
jiang University City College Animal Care Facility. The
animal procedures were approved by the Committee on
the Ethics of Animal Experiments of Zhejiang University
and were carried out in accordance with Zhejiang Univer-
sity Institutional Animal Care and Use Committee (Per-
mit number: ZJU2015-489-02).
Focal cerebral ischemia models
To induce focal cerebral ischemia, rats were subjected to
MCAO as reported previously.17 Briefly, rats were fasted
overnight before operation but had free access to water.
The next day, rats were anesthetized with 10% isoflurane
and the common carotid artery, external carotid artery,
and internal carotid artery were exposed through a mid-
line incision. A monofilament nylon suture was inserted
through the ICA toward the cranial base until feeling a
mild resistance. At this stage, cerebral blood flow value
was detected by LDF measurement and an approximately
80% drop of the baseline blood flow value was considered
MCA occlusion. The suture was withdrawn after 1–6 h to
allow reperfusion. Similar surgical procedure was con-
ducted in sham animals without introducing the occlud-
ing suture. Rectal temperature was maintained at
37  0.5°C during the operation and during recovery
from the operation.
Drug treatment
Rapamycin (LC Laboratories, USA) stock solution was
prepared by dissolving 30 mg in 1 mL of 100% ethanol
and stored at 20°C. It was diluted in 5% Tween 80, 5%
polyethyleneglycol 400 and 4% ethanol immediately
before use.18 Rapamycin was injected intraperitoneal once
a day at the dose of 3.0 mg/kg. For rapamycin pretreat-
ment group (prerapa), rats were administrated rapamycin
for consecutive 3 day, and MCAO was conducted 24 h
after the last injection. For rapamycin posttreatment
group (post-rapa), rats were administrated rapamycin 6 h
after MCAO and another consecutive 3 day. For vehicle-
treated group (veh), rats received the same volume of
vehicle in all experiments.
Neurobehavioral testing
Modified neurological severity score (NSS) was used to
access their neurobehavioral change.19 Neurological func-
tion included motor tests, sensory tests, beam balance test,
and reflex absence and abnormal movements, which all
were graded on a scale of 0–18 (normal score, 0; maximal
deficit score, 18). Rats were trained before operation, and
then were assessed 1, 3, 7, 10, and 14 days after MCAO.
The observers were blinded to the treatment group.
Infarct volume measurement
Rats were decapitated 4 days after MCAO and brains
were rapidly removed. Coronal sections with the thickness
of 2 mm were stained with 2% 2,3,5-triphenyltetrazolium
chloride (TTC) (Solarbio, China) for 30 min at 37°C fol-
lowed by immersion in 4% paraformaldehyde solution
overnight and photographed by a digital camera. Micro-
scope image-analysis software (Image-Pro plus, USA) was
used to calculate the infarct volumes as previously
reported.20 Briefly, infarct area of each brain section was
added to obtain the total infarct areas. The infarct volume
was obtained by multiplying the total infarct areas to the
thickness of the sections. The percentage of infarct vol-
ume to total brain volume represents the degree of cere-
bral infarction.
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Western blotting analysis
Proteins expression in the ischemic core, ischemic
penumbra, and contralateral normal brain were detected
by standard methods as previously described.21 Proteins
were separated and transferred onto polyvinylidene fluo-
ride membrane (Millpore, USA). The membrane was
blocked with 5% skim milk followed by the primary anti-
body of phospho-Akt(Ser473), phospho-mTOR(Ser2448),
phospho-p70s6 kinase (Thr389), phospho-S6 (Ser240/
244), cleaved caspase-9, cleaved caspase-3, phospho-ULK1
(Ser757), Beclin1(Abcam, UK), and LC3(Abcam) over-
night at 4°C, respectively. The membrane was then incu-
bated with the peroxidase conjugated anti-rabbit or anti-
mouse secondary antibody (Pierce, 1:5000, USA).
Enhanced chemiluminescence reagent (Pierce) was used
to visualize the protein signals. The membranes were
reprobed and incubated with the rabbit Akt antibody,
rabbit mTOR antibody, rabbit p70S6 kinase antibody,
rabbit S6 antibody, rabbit ULK1 antibody, and mouseb-
actin, respectively. Except Beclin 1 and LC3 antibody were
obtained from Abcam, all other antibodies were pur-
chased from Cell Signaling Technology and diluted
according to the ratio 1:1000. Intensity of the signals was
measured by Image J (NIH, USA). The results were pre-
sented as a ratio of phosphorylation to total protein or to
actin. Each experiment was conducted independently at
least three times.
Fluoro-Jade B staining
Seven days after operation, rats were deeply anesthetized
and perfused transcardially with saline, subsequently fol-
lowed by 4% paraformaldehyde in 0.1 mol/L phosphate
buffer (pH 7.4). Brains were postfixed with 4%
paraformaldehyde, and then dehydrated in ascending con-
centration of sucrose. After embedded in Tissue-Tek OCT,
brains were sectioned at 20 lm thickness. Fluoro-Jade B
staining was conducted as described previously.22 Tissues
were first placed in 0.1 mol/L phosphate buffer. They were
then treated in turn with 1% NaOH in 80% ethanol for
5 min, 70% ethanol for 2 min, ddH2O for 2 min, 0.06%
KMnO4 for 10 min, and ddH2O for 2 min. Tissues were
transferred into 0.001% Fluoro-Jade B in 0.1% acetic acid
for 20 min and washed three times with ddH2O for 1 min
each and dried overnight. Finally, the sections were
mounted on glass slides and imaged using a fluorescence
microscope. FJB-positive cells in each field were calculated.
Statistical analysis
Quantitative results were expressed as mean  SEM.
One-way ANOVA with SNK-Q test for post hoc multiple
comparisons (version 16.0, SPSS Inc., Chicago, IL) was
used to analyze the differences among groups. P < 0.05
was considered statistically significant.
Results
mTOR signaling pathway was changed
differentially in different brain zones
following MCAO
The area lying just outside the ischemic core region
(tissue most severely damaged by stroke or ischemic
event) was termed the ischemic penumbra. It has the
potential for recovery and therefore is the target for
interventional therapy in acute ischemic stroke.23 In this
study, we first stained the coronal brain section by
TTC staining at 3 h after ischemia without reperfusion
Figure 1. mTOR signaling pathway was activated in ischemic penumbra but inhibited in ischemic core. (A) Partition of brain slices by TTC
staining after MCAO. (I) normal zone; (II) ischemic penumbra; (III) ischemic core. (B) Representative LDF image during MCAO. (C) Representative
western blots of Akt, mTOR, S6K, and S6 in normal zone, ischemic penumbra, and ischemic core. (D) Quantitative summary demonstrated that
the phosphorylation of the four proteins was significantly increased in ischemic penumbra but decreased in ischemic core. (*P < 0.05,
**P < 0.01vs. normal zones, #P < 0.05 vs. ischemic penumbra, n = 6/group).
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and partitioned it into three parts: (I) normal zone;
(II) ischemic penumbra; (III) ischemic core (Fig. 1A).
Then, we analyzed the changes in the four key proteins
in these three parts. The results showed that the
expression of Akt, mTOR, S6K, and S6 phosphorylation
was significantly increased in the ischemic penumbra
but markedly decreased in ischemic core as compared
with the normal zone (Fig. 1B–C). Similar results were
also demonstrated at other time points of 1 h and 6 h
(data not shown). These results suggested that mTOR
signaling pathway was abnormally activated in ischemic
penumbra while inhibited in ischemic core.
Changes in mTOR signaling pathway at
different ischemic intervals with or without
reperfusion
Next, we observed the changes in mTOR signaling path-
way reflected by S6 phosphorylation in the ischemic
penumbra at different ischemia/reperfusion intervals after
Figure 2. Expression of S6 phosphorylation at different ischemia/reperfusion intervals after MCAO. (A) Representative western blots of p-S6
expression at different ischemia time after MCAO. (B) Quantitative summary demonstrated that the expression of p-S6 was significantly increased
in ischemic penumbra 1 h after MCAO and remained elevated for 6 h. (C, E) Representative western blots of p-S6 expression at different intervals
of reperfusion after 1 h ischemia. (D, F) Quantitative summary demonstrated that the expression of p-S6 was significantly increased in ischemic
penumbra after 1–24 h reperfusion and gradually reduced thereafter. (*P < 0.05, **P < 0.01 vs. normal zones, n = 6/group).
Figure 3. Expression of apoptosis and autophagy-related proteins after MCAO. (A) Representative western blots of cleaved caspase 9 and
caspase 3 at 24 h and 7 days after MCAO. (B) Quantitative summary demonstrated that the expression of cleaved caspase 9 and caspase 3 was
significantly increased both in ischemic penumbra and ischemic core at 24 h and 7 day after MCAO. (C) Representative western blots of p-ULK1,
beclin 1, and LC3 expression at 24 h and 7 day after MCAO. (D-F) Quantitative summary demonstrated that the expression of p-ULK1, beclin 1,
and LC3 was significantly decreased both in ischemic penumbra and ischemic core at 24 h and 7 day after MCAO. (*P < 0.05, **P < 0.01 vs.
normal zones, n = 6/group).
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MCAO. The expression of p-S6 phosphorylation levels
did not change significantly after 30 min of ischemia,
however, it increased markedly starting from 1 h and
maintained at a high level until 6 h after ischemia
(Fig. 2A–B). Since the mortality rate of rats was increased
along with the prolongation of ischemic time, we deter-
mined the ischemia time as 1.5 h followed by reperfusion
for the following experiments.
We then detect the change in p-S6 expression after dif-
ferent reperfusion intervals. The expression of phospho-
S6 was markedly elevated within 6 h after reperfusion
(Fig.2C–D), it reached a peak value at 1 d and decreased
gradually thereafter but still maintained at an elevated
level till 14 d (Fig. 2E–F) or even 6 w (data not shown).
The above results suggested that mTOR signaling pathway
was activated after ischemia with and without reperfu-
sion.
Changes in apoptosis and autophagy in
different brain zones
Many cross-talk pathways are observed between apoptosis
and autophagy involving mTOR signaling. We also
observed changes in apoptosis- and autophagy-related
proteins after MCAO in different brain zones. As com-
pared to normal zone, the expression of cleaved caspase-9
and caspase-3 was elevated both in ischemic penumbra
and in ischemic core as detected 24 h and 7 day after
MCAO (Fig. 3A and B). In contrast, the level of phos-
phorylated ULK1, Beclin 1, and LC3-II was decreased
both in ischemic penumbra and in ischemic core as
detected 24 h and 7 day after MCAO (Fig. 3C–F). These
data indicate that I/R injury results in neuronal apoptosis
and inhibition of autophagy activity.
Rapamycin inhibited mTOR signaling
pathway and improved neurologic deficits
To detect whether activation of mTOR signaling pathway in
ischemic penumbra is beneficial or detrimental to I/R
injury, we treated rats with mTOR inhibitor rapamycin
before or after MCAO and killed the rats for western blot
analysis 3 day after MCAO. Compared with the vehicle-
treated model group, the expression of p-S6 was signifi-
cantly inhibited both in pre and postrapamycin-treated
group (Fig. 4A–B). Another cohort of rats was evaluated for
neurological function at 1, 3, 7, 10, and 14 day by NSS
score. Left-biased swing was also tested to evaluate the
asymmetry of movement at 7 day and 14 day. Compared
with the sham group, the vehicle-treated group showed an
obvious increase in NSS score at all time points. However,
the NSS score in pre and postrapamycin-treated group were
significantly decreased in 7, 10, and 14 days after MCAO
(Fig. 4C). Similar results were also exhibited in the left-
Figure 4. Rapamycin administration inhibited mTOR signaling pathway and improved neurologic deficits. (A) Representative western blots of p-S6
expression after pre or posttreatment of rapamycin. (B) Quantitative summary demonstrated that the expression of p-S6 was significantly reduced
with pre and postrapamycin treatment. (C) Assessment of neurological severity scores in different groups within 14 days after MCAO. The scores
were significantly lower in pre and postrapamycin group as compared with the vehicle group at 7, 10, and 14 day. (D) Rapamycin treatment
improved asymmetrical motor function at 7 days and 14 days after MCAO in the elevated body swing test. (**P < 0.01 vs. sham group,
#P < 0.05, ##P < 0.01 vs. vehicle group, n = 6 in A and B, n = 10 in C and D per group).
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biased swing test (Fig. 4D). The results indicate that rapa-
mycin reverses the abnormal activation of mTOR signaling
pathways caused by cerebral ischemia–reperfusion and sig-
nificantly improves the associated neurological deficits.
Rapamycin treatment reduced the infarct
volume in MCAO rats
Rats were killed 3 day after MCAO and the infarct vol-
ume was calculated after TTC staining. No obvious
infarct area was noticed in sham group. The infarct vol-
ume was 28.4  3.1% of total brain volume in the vehi-
cle-treated group, whereas rapamycin pre and posttreated
groups exhibited markedly decrease in infarct volume of
15.8  2.9% and 20.1  1.8%, respectively (Fig. 5A–B).
Rapamycin treatment reduced neuronal
apoptosis and increased activation of
autophagy
To characterize the apoptosis of neurons after ischemia–
reperfusion injury in different groups, we performed Flu-
oro-Jade B staining 7 day after MCAO. No obvious FJB-
positive cells were shown in sham group, however, it was
robust in vehicle-treated I/R modeling rats in ischemic
penumbra. Although FJB-positive cells were also abun-
dant in both pre and postrapamycin-treated group as
compared with sham group, it was significantly less than
that in the vehicle-treated group (Fig. 6A–B). Similar
results were also obtained at other time points of 3 days
and 2 week after MCAO (data not shown). Accordingly,
cleaved caspase-9 and cleaved caspase-3 was markedly
increased in vehicle-treated group in ischemic penumbra,
whereas pre and postrapamycin administration alleviated
the increase in cleaved caspase-9 and cleaved caspase-3
(Fig. 6C–D). Similarly, pre and postrapamycin adminis-
tration increased the expression of phosphorylated ULK1,
Beclin 1, and LC3-II proteins (Fig. 6E–F).
Discussion
The results presented in this work revealed that mTOR
signaling pathway is abnormally activated in ischemic
penumbra and inhibited in ischemic core after MCAO.
Increased apotosis and decreased autophagy activity are
demonstrated both in ischemic penumbra and ischemic
core. Rapamycin administration significantly reduces
lesion volumes and neuronal apoptosis and improves
autophagy and motor function, implying a new direction
for the treatment of cerebral ischemia.
A complicated cascade of pathophysiological events is
involved in the development of I/R injury including exci-
totoxicity, oxidative stress, inflammation, and apoptosis
which is proposed in the ischemic penumbra zone. Since
mTOR signaling pathway plays a pivotal role regarding all
the above pathophysiological process, it has been widely
studied in brain ischemia. Activation of mTOR signaling
pathway in nude mice significantly reduces cerebral ische-
mia injury as well as reduce neurological deficit, infarct
areas and brain water content.11–13,24,25 However, inhibit-
ing mTOR signaling pathway using rapamycin or knock-
down of mTOR promotes autophagy and attenuates
ischemia-induced neuronal death.14–16,26 Reports also
demonstrate that inhibition of mTOR pathway suppresses
autophagy, prevents cytochromecrelease and reduces
ischemic brain damage.3,15,27 This discrepancy may result
from different animal strains, ischemic model, the time
and route of drug administration. In this study, we first
performed a more detailed temporal analysis of mTOR
signaling changes in normal zone, ischemic penumbra
and ischemic core of the MCAO model in rat. We found
that mTOR pathway was activated in ischemic penumbra
and suppressed in ischemic core for at least 2 weeks.
According to our results, it is reasonable to hypothesize
that upregulating the mTOR pathway in ischemic core
and downregulating the mTOR pathway in ischemic
Figure 5. Rapamycin treatment decreased infarct volume. (A)
Representative slices of TTC staining. (B) Quantitative analyses of
infarct volume. Rapamycin treatment significantly reduced infarction
volumes. (**P < 0.01 vs. sham group, ##P < 0.01 vs. vehicle group,
n = 12 per group).
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penumbra may benefit the treatment of ischemia–reperfu-
sion injury. Since the neurons in ischemic core are diffi-
cult to rescue, we used rapamycin as an inhibitor to
suppress the over activation of mTOR in ischemic
penumbra, a zone which can be transferred to normal
zone under appropriate treatment. As we expected, rapa-
mycin protected the ischemia–reperfusion injury by
reducing the infarct volume and neurological deficit.
Rapamycin has diverse effect by inhibiting mTOR path-
way. First, rapamycin has dual effects on apoptosis.28 On
one hand, rapamycin is proved to be proapoptotic, espe-
cially in cancers, resulting in apoptotic death of the can-
cer cells.29 On the other hand, some evidence has
demonstrated that rapamycin can be antiapoptotic.30,31
For example, rapamycin inhibits death of syncytia via
inhibition of proapoptotic Bax and inhibition of the
mitochondrial cell death pathway.32,33 In neurodegenera-
tive diseases, rapamycin inhibited high expression of
mTOR and improved the level of antiapoptotic protein
Bcl-2. It also induced autophagy and inhibited cell apop-
tosis, thus playing the effect of neuroprotection.34,35 Sec-
ond, rapamycin has anti-inflammatory effects. Rapamycin
apparently attenuates behavioral deficits after MCAO by
shifting the microglia phenotype from M1 type to M2
type.36 It can attenuate secondary injury after focal ische-
mia by enhancing anti-inflammatory activity of Tregs to
restrain neuroinflammation.4 In addition, rapamycin can
inhibit astrocyte proliferation, migration and production
of inflammatory mediators after oxygen-glucose depriva-
tion/reoxygenation.37 Third, rapamycin has a paradoxical
effect on oxidative stress. On one hand, rapamycin can
reduce oxidative stress in a rat of Parkinson model and
restores the mitophagy inhibited by monoamine oxidase
B (Mao-B) in an inducible cell model.38,39 On the other
hand, rapamycin increases oxidative stress response in
adult stem cells40 and nucleolar disruption leads to oxida-
tive damage and Parkinsonism through mTOR repres-
sion.41 Fourth, rapamycin can induce autophagy.
Rapamycin activates autophagy to rescue the neurons des-
tined to die in global ischemia and in neonatal hypoxia-
ischemia.42,43 In our study, mTOR signaling pathway is
abnormally activated in ischemic penumbra, and neurnal
apoptosis is activated, whereas autophagy was inhibited.
Rapamycin inhibits the activation of mTOR pathway,
reduced cell apoptosis and activate autophagy in ischemic
penumbra, suggested that rapamycin has a protective
effect on cerebral ischemia–reperfusion injury in SD rats.
This study also demonstrated that both rapamycin pre
and posttreatment had similar effect, indicating that rapa-
mycin exerts its neuroprotective effect in cerebral ische-
mia may be associated with the later development of
ischemia–reperfusion injury. Since currently available
Figure 6. Rapamycin treatment reduced neuronal apoptosis and activated autophagy. (A) Representative photographs of FJB staining. (B)
Quantitative analyses of FJB staining. The number of FJB-positive cells was markedly decreased after rapamycin treatment. (C) Representative
western blots of cleaved caspase 9 and caspase 3 expression after rapamycin treatment. (D) Quantitative summary demonstrated that the
expression of cleaved caspase 9 and caspase 3 was significantly decreased in pre and postrapamycin treatment. (E) Representative western blots
of p-ULK1, Beclin 1 and LC 3 expression after rapamycin treatment. (F) Quantitative summary demonstrated that the expression of p-ULK1, Beclin
1 and LC 3 was significantly increased in pre and postrapamycin treatment. (**P < 0.01 vs. sham group,#p < 0.05,##P < 0.01 vs. vehicle group,
n = 6 per group, Scale bar = 100 lm).
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treatment of tPA has a strict time window, rapamycin
may be considered as an alternative drug that used for
brain stroke treatment when tPA is counterindicated.
Additional studies are needed to determine the specific
mechanisms of rapamycin’s neuroprotective effect in
stroke and its potential translational applications.
In conclusion, our data showed that mTOR signaling
pathway was abnormally activated in ischemic penum-
bra. mTOR inhibitor rapamycin administrated before or
after MCAO improves the neurologic function and
decreases the infarct volume by decreasing the number
of neurons apoptosis and activating of autophagy pro-
cess. These results indicate that mTOR signaling path-
way is a potential target for neuroprotection in
ischemic brain treatment, but the specific mechanism
needs further study.
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